ESCRS 2023: New artificial intelligence integrations are ahead for iCare

News
Video

The diagnostics company is using AI to screen for diabetic retinopathy, glaucoma and age-related macular degeneration

Artificial intelligence (AI) was a popular topic at this year’s European Society of Cataract and Refractive Surgeons (ESCRS) meeting. At the meeting, our team stopped by the iCare booth to see how AI is improving diagnostic speed and accuracy, for patients of all ages.


Editor's note: The below transcript has been lightly edited for clarity.

Kasperi Kankare: I'm Kasperi Kankare. I'm a key account manager at iCare Finland.

iCare has brought to the ESCRS this year 3 fantastic and unique solutions. We brought something new to glaucoma, we have brought the new iCare IC200, which is faster than ever and with its new quick measurement mode, it also enables measuring paediatric patients, from infants to the grownups, in a 200-degree angle, a complete freedom. Also we have iCare home, which enables the patient to do a home tonometry, which then can deliver the true intraocular pressure value to ophthalmologists and caregivers. And most importantly for glaucoma, we have now brought the new COMPASS. It delivers [an] absolutely fantastic visual field examination within just 4 minutes without [a] trial lens. I would enable the combined COMPASS with the iCare home. Because how you can treat glaucoma without knowing the true intraocular pressure of the patient?

On retina, iCare has always been leading a retina camera manufacturer. Our proprietary true color technology delivers a clear, high contrast image. The iCare ILLUME is the perfect marriage of our DRSplus fully-automatic retinal imaging solution, combined with a cloud service and artificial intelligence, which enables a caregiver to do a patient screening for 3 pathologies: diabetic retinopathy, AMD and glaucoma. Within a time period of 3 minutes from the imaging to the AI report. We have a lot of new interesting things upcoming. What I personally am awaiting most is to work with the artificial intelligence in ILLUME, because that is truly game-changing in our field.


Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.